Cargando…

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to occur through modified atherosclerotic progression. In this study, both of the compounds significantly attenuated plaque les...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakipovski, Günaj, Rolin, Bidda, Nøhr, Jane, Klewe, Ib, Frederiksen, Klaus S., Augustin, Robert, Hecksher-Sørensen, Jacob, Ingvorsen, Camilla, Polex-Wolf, Joseph, Knudsen, Lotte Bjerre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	PRECLINICAL RESEARCH
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314963/ https://www.ncbi.nlm.nih.gov/pubmed/30623143 http://dx.doi.org/10.1016/j.jacbts.2018.09.004

Ejemplares similares

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels
por: Punjabi, Mukesh, et al.
Publicado: (2022)

Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
por: Bisgaard, Line S., et al.
Publicado: (2016)

Semaglutide treatment attenuates vessel remodelling in ApoE−/− mice following vascular injury and blood flow perturbation
por: Jensen, Ditte Marie, et al.
Publicado: (2022)

MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of LDLr Missense Variants
por: Larrea-Sebal, Asier, et al.
Publicado: (2021)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs
por: Ipsen, David Højland, et al.
Publicado: (2016)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

High-Fat Diet Enhances Neutrophil Adhesion in LDLR-Null Mice Via Hypercitrullination of Histone H3
por: Osaka, Mizuko, et al.
Publicado: (2021)

Deep learning reveals 3D atherosclerotic plaque distribution and composition
por: Jurtz, Vanessa Isabell, et al.
Publicado: (2020)

Pulsatile Hyperglycaemia Induces Vascular Oxidative Stress and GLUT 1 Expression More Potently than Sustained Hyperglycaemia in Rats on High Fat Diet
por: Rakipovski, Günaj, et al.
Publicado: (2016)

T Cells in Atherosclerosis in Ldlr−/− and Apoe−/− Mice
por: Getz, Godfrey S., et al.
Publicado: (2018)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
por: Inia, José A., et al.
Publicado: (2023)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
por: Petersen, Karen Ekkelund, et al.
Publicado: (2016)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
por: Alsugair, Hassan A., et al.
Publicado: (2021)

Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment
por: Salinas, Casper Bo Gravesen, et al.
Publicado: (2018)

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2020)

Atherogenesis in Apoe(−/−) and Ldlr(−/−) Mice with a Genetically Resistant Background
por: Torikai, Hideyuki, et al.
Publicado: (2023)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation
por: Klaebel, Julie Hviid, et al.
Publicado: (2020)

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease
por: Hansen, Henrik H., et al.
Publicado: (2015)

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2021)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?
por: Stoll, Lisa, et al.
Publicado: (2023)

APOE and LDLR Gene Polymorphisms and Dyslipidemia Tracking. Rio de Janeiro Study
por: de Freitas, Rossana Ghessa Andrade, et al.
Publicado: (2015)

Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2016)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Uptake of (68)gallium in atherosclerotic plaques in LDLR(-/-)ApoB(100/100 )mice
por: Silvola, Johanna MU, et al.
Publicado: (2011)

Different Susceptibilities between Apoe- and Ldlr-Deficient Mice to Inflammation-Associated Colorectal Carcinogenesis
por: Tanaka, Takuji, et al.
Publicado: (2016)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Suppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models
por: Rupp, Alan C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9nji1lplbebrhmg9kranvq7rtq